The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 806 participants.

Also called NCT04781114

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 806 participants (enrolled count) (from the registry)
Sponsor
Shanghai Junshi Bioscience Co., Ltd. (from the registry)
Registry
  • NCT NCT04781114
Other papers using this trial's data
  • Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia Journal of the American Heart Association, 2024-06-04 DOI, PubMed 38818934, PMC11255649 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04781114. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-23 (actual); primary completion 2022-05-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
Condition
Hyperlipemia
Intervention (Drug)
JS002
Intervention (Drug)
Placebo
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct04781114
Content hash
405184fb559d4beba1ef0a8eb08405f9af3e6c181ceb79aa161cbe179d8fa4ef